| MCyR | CCyR | MMR | MR4.0 | MR4.5 | |||||
---|---|---|---|---|---|---|---|---|---|---|
 | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
In 164 evaluable patients | ||||||||||
Baseline BCR-ABL1 mutation status by Sanger sequencing |  | 0.10 |  | 0.02 |  | 0.006 |  | 0.006 |  |  < 0.001 |
Single T315I mutation (ref.) | ||||||||||
T315I + additional mutations | 0.6 (0.3–1.0) | 0.05 | 0.6 (0.3–1.1) | 0.10 | 0.8 (0.4–1.3) | 0.32 | 0.4 (0.2–1.0) | 0.05 | 0.5 (0.2–1.1) | 0.10 |
Other mutations | 0.7 (0.5–1.2) | 0.21 | 0.6 (0.3–1.0) | 0.06 | 1.0 (0.5–1.8) | 0.80 | 0.6 (0.3–1.3) | 0.23 | 0.4 (0.1–1.6) | 0.22 |
No mutation | 0.6 (0.4–1.1) | 0.13 | 0.5 (0.3–0.8) | 0.009 | 1.0 (0.0–0.4) |  < 0.001 | 0.1 (0.0–0.4) | 0.005 | 0.0 (0.0–0.0) |  < 0.001 |
Accelerated phase (ref. chronic phase) | 0.5 (0.3–1.0) | 0.04 | 0.5 (0.3–0.9) | 0.03 | 0.6 (0.4–1.0) | 0.06 | 0.7 (0.4–1.3) | 0.29 | 0.8 (0.4–1.5) | 0.51 |
Additional chromosomal abnormalities (ref. none) | 0.7 (0.4–1.2) | 0.18 | 0.7 (0.4–1.3) | 0.23 | 0.7 (0.4–1.3) | 0.24 | 0.8 (0.4–1.6) | 0.49 | 0.6 (0.3–1.6) | 0.33 |
Time from diagnosis to olverembatinib treatment, years (continuous) | 0.9 (0. 9–1.0) | 0.002 | 1.0 (0.9–1.0) | 0.003 | 1.0 (0.9–1.0) |  < 0.001 | 1.0 (0.9–1.0) | 0.002 | 0.9 (0.8–1.0) |  < 0.001 |
Number of prior TKIs (continuous) | 0.8 (0.6–1.1) | 0.16 | 0.7 (0.5–1.1) | 0.10 | 0.7 (0.5–1.0) | 0.03 | 0.7 (0.5–1.1) | 0.12 | 0.8 (0.5–1.2) | 0.27 |
Age (10 years) | 0.9 (0.8–1.1) | 0.36 | 0.8 (0.7–1.0) | 0.07 | 0.9 (0.8–1.1) | 0.30 | 0.9 (0.8–1.1) | 0.44 | 1.0 (0.8–1.2) | 0.90 |
In 118 evaluable patients | ||||||||||
Baseline BCR-ABL1 mutation status by next-generation sequencing |  | 0.31 |  | 0.13 |  | 0.002 |  |  < 0.001 |  |  < 0.001 |
Single T315I mutation (ref.) | ||||||||||
T315I + additional mutations | 0.6 (0.3–1.2) | 0.15 | 0.7 (0.3–1.4) | 0.26 | 0.4 (0.1–0.9) | 0.03 | 0.5 (0.2–1.2) | 0.13 | 0.7 (0.3–1.5) | 0.35 |
Other mutations | 0.7 (0.4–1.5) | 0.40 | 0.6 (0.3–1.2) | 0.14 | 0.8 (0.4–1.9) | 0.67 | 0.7 (0.3–1.6) | 0.42 | 0.5 (0.1–1.9) | 0.29 |
Compound mutations | 0.6 (0.3–1.2) | 0.13 | 0.7 (0.3–1.4) | 0.26 | 0.6 (0.3–1.2) | 0.16 | 0.3 (0.1–1.1) | 0.07 | 0.4 (0.1–1.2) | 0.11 |
No mutation | 0.7 (0.3–1.2) | 0.15 | 0.5 (0.3–0.9) | 0.02 | 0.0 (0.0–0.2) |  < 0.001 | 0.0 (0.0–0.0) |  < 0.001 | 0.0 (0.0–0.0) |  < 0.001 |
Accelerated phase (ref. chronic phase) | 0.8 (0.7–1.0) | 0.10 | 0.8 (0.6–1.0) | 0.03 | 0.9 (0.7–1.1) | 0.21 | 0.9 (0.7–1.1) | 0.45 | 1.0 (0.8–1.3) | 0.82 |
Additional chromosomal abnormalities (ref. none) | 0.3 (0.2–0.7) | 0.004 | 0.4 (0.2–0.8) | 0.007 | 0.4 (0.2–0.8) | 0.009 | 0.7 (0.3–1.4) | 0.32 | 0.8 (0.4–1.7) | 0.59 |
Time from diagnosis to olverembatinib treatment, years (continuous) | 0.9 (0.8–1.0) | 0.003 | 1.0 (0.8–1.0) | 0.004 | 0.9 (0.8–1.0) |  < 0.001 | 0.9 (0.8–1.0) | 0.003 | 0.9 (0.8–1.0) | 0.002 |
Number of prior TKIs (continuous) | 0.7 (0.4–1.0) | 0.03 | 0.6 (0.4–1.0) | 0.02 | 0.6 (0.4–0.9) | 0.01 | 0.7 (0.4–1.0) | 0.08 | 0.8 (0.5–1.3) | 0.33 |
Age (10 years) | 0.8 (0.7–1.0) | 0.10 | 0.8 (0.6–1.0) | 0.03 | 0.9 (0.7–1.1) | 0.21 | 0.9 (0.7–1.1) | 0.45 | 1.0 (0.8–1.3) | 0.82 |